Document:

​

Exhibit 10.2
​
EXECUTION COPY
CONFIDENTIAL
​
STOCK PURCHASE AGREEMENT
​
THIS STOCK PURCHASE AGREEMENT (“Agreement”) is entered into as of February 2, 2021 (the “Execution Date”), by and between Shanghai Junshi Biosciences Co., Ltd., a company organized under the laws of the People’s Republic of China, having its place of business at Level 13, Building 2, Nos. 36 and 58, Hai Qu Road, China (Shanghai) Pilot Free Trade Zone, the PRC (“Junshi”), and Coherus BioSciences, Inc., a Delaware corporation having its principal place of business at 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 (“Coherus”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1.
​
RECITALS
​
Coherus has agreed to sell, and Junshi has agreed to purchase, shares of Common Stock subject to and in accordance with the terms and provisions of this Agreement.
​
AGREEMENT
​
For good and valuable consideration, the Parties agree as follows:
​
Section 1. SALE AND PURCHASE OF STOCK
​
1.1Purchase of Stock. Subject to the terms and conditions of this Agreement, at the Closing, Coherus will issue and sell to Junshi, and Junshi will purchase from Coherus 2,491,988 shares of Common Stock, which number of shares of Common Stock is equal to the quotient of (a) $50,000,000 divided by (b) $20.0643, being the daily weighted average price per share of the Common Stock on Nasdaq over the ten (10) trading day period ending on and including the last trading day prior to the execution date of the Collaboration Agreement (the “Per Share Price”), rounded down to the nearest whole number of shares of Common Stock, (the shares of Common Stock represented by such formula, the “Shares”) for an aggregate purchase price equal to $50,000,000 (the “Purchase Price”).
​
1.2Payment. At the Closing, Junshi will pay the Purchase Price by wire transfer of immediately available funds in accordance with wire instructions provided by Coherus to Junshi at least seven (7) Business Days prior to the Closing, and Coherus will deliver the Shares in book-entry form to Junshi upon receipt of the Purchase Price.
​
1.3Closing.
​
(a)Closing. The closing of the transaction contemplated by Section 1.1 (the “Closing”) will be held within seven (7) Business Days after the conditions to closing set forth in Section 7 are satisfied or waived for the Closing (other than those conditions that by their nature are to be satisfied or waived at the Closing) or at such other time and/or date as may be jointly designated by Junshi and Coherus for the Closing.
​
​

​

​

​
		(b)
	Closing Deliverables.

​
		(i)
	At the Closing, Coherus will deliver to Junshi:

​
(1)a duly executed cross-receipt for the Purchase Price in exchange for the issuance of the Shares in form and substance reasonably satisfactory to each party; and
​
(2)a certificate in form and substance reasonably satisfactory to Junshi and duly executed on behalf of Coherus by an authorized officer of Coherus, certifying that the conditions to Closing set forth in Section 7.2 have been fulfilled.
​
		(ii)
	At the Closing, Junshi will deliver to Coherus:

​
(1)the Purchase Price by wire transfer of immediately available funds pursuant to Section 1.2;
​
(2)a duly executed cross-receipt for the Shares in exchange for the receipt of the Purchase Price; and
​
(3)a certificate in form and substance reasonably satisfactory to Coherus and duly executed on behalf of Junshi by an authorized officer of Junshi, certifying that the conditions to Closing set forth in Section 7.1 have been fulfilled.
​
(iii)As promptly as practicable following the Closing, Coherus will deliver to Junshi evidence from its transfer agent that the Shares have been issued to Junshi in book-entry form.
​
Section 2. REPRESENTATIONS AND WARRANTIES OF COHERUS
​
Except as otherwise specifically contemplated by this Agreement, Coherus hereby represents and warrants to Junshi that:
​
2.1Private Placement; No General Solicitation. Subject to the accuracy of the representations made by Junshi in Section 3, the offer, issuance and sale of the Shares to Junshi as contemplated hereby are exempt from the registration requirements of the Securities Act. Coherus has not engaged any brokers, finders, placement agents or other agents, or incurred, or will incur, directly or indirectly, any liability for brokerage or finder’s or financial advisory fees or agents’ commissions or any similar charges in connection with this Agreement and the transactions contemplated hereby. Coherus has not engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the Shares.
​
2.2Organization and Qualification. Each of Coherus and its subsidiaries is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, with full corporate, limited liability company or similar organizational power and authority to conduct its business as currently conducted. Each of Coherus and its subsidiaries is duly
​
​

2

​

​
qualified to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected to have a Material Adverse Effect.
​
2.3Authorization; Enforcement. Coherus has all requisite corporate power and authority to enter into and to perform its obligations under this Agreement, to consummate the transactions contemplated hereby and to issue the Shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by Coherus and the consummation by it of the transactions contemplated hereby (including the issuance of the Shares at the Closing in accordance with the terms hereof) have been duly authorized by the Board and no further consent or authorization of Coherus, the Board or its stockholders is required. This Agreement has been duly executed by Coherus and constitutes a legal, valid and binding obligation of Coherus enforceable against Coherus in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization or moratorium or similar laws affecting creditors’ and contracting parties’ rights generally, and except as enforceability may be subject to general principles of equity and except as rights to indemnity and contribution may be limited by state or federal securities laws or public policy underlying such laws.
​
2.4Issuance of Shares. The Shares are duly authorized and, upon issuance in accordance with the terms of this Agreement, will be validly issued, fully paid and non- assessable, free and clear of all Liens (except for the restrictions set forth in this Agreement or under applicable securities laws) and will not be subject to preemptive rights or other similar rights of stockholders of Coherus.
​
		2.5
	SEC Documents, Financial Statements.

​
(a)The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act. Coherus has delivered or made available (by filing on the SEC’s electronic data gathering and retrieval system (EDGAR)) to Junshi complete copies of its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q, and any report on Form 8-K, in each case filed with the SEC after January 1, 2020 and prior to the Execution Date (the “SEC Documents”). As of its respective date, each SEC Document complied as to form in all material respects with the requirements of the Exchange Act and, as of its respective date, each SEC Document did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
​
(b)As of its respective date, the financial statements, together with the related notes and schedules, of Coherus included in the SEC Documents complied as to form in all material respects with all applicable accounting requirements and the published rules and regulations of the SEC and all other applicable rules and regulations with respect thereto. Such financial statements, together with the related notes and schedules, have been prepared in accordance with GAAP applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed
​
​

3

​

​
or summary statements), and fairly present in all material respects the financial condition of Coherus and its consolidated subsidiaries as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as disclosed on or reflected or reserved against in, the financial statements, Coherus has not, and is not subject to any material liabilities of the type required to be disclosed in the financial statements, except (i) liabilities incurred in the ordinary course of business since the date of its most recent financial statements (none of which is resulting from a breach of contract, breach of warranty, tort, infringement, claim or lawsuit), (ii) liabilities that were incurred under any contract or agreement to which Coherus is a party (but, in each case, none of which resulted from a breach thereof), or (iii) liabilities incurred as a result of or arising out of the transactions contemplated under this Agreement.
​
(c)The Common Stock is listed on Nasdaq, and Coherus has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq. Coherus has not received any notification that, and has no knowledge that, the SEC or Nasdaq is contemplating terminating such registration or listing.
​
2.6Internal Controls; Disclosure Controls and Procedures. Coherus maintains internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Coherus has implemented the “disclosure controls and procedures” (as defined in Rules 13a- 15(e) and 15d-15(e) under the Exchange Act) required in order for the principal executive officer and principal financial officer of Coherus to engage in the review and evaluation process mandated by the Exchange Act, and is in compliance with such disclosure controls and procedures in all material respects. Each of the principal executive officer and the principal financial officer of Coherus has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 with respect to all reports, schedules, forms, statements and other documents required to be filed by Coherus with the SEC after January 1, 2020. Since January 1, 2020, neither Coherus, nor, to Coherus’ knowledge, any of Coherus’ employees or independent auditors, has identified or been made aware of (a) any significant deficiency or material weakness (as defined in Rule 12b-2 under the Exchange Act) in the system of internal  accounting controls utilized by Coherus, (b) any fraud, whether or not material, that involves Coherus’ management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by Coherus or (c) any claim or allegation regarding any of clauses (a) and (b), in each case, except to the extent disclosed in the SEC Documents.
​
2.7Capitalization and Voting Rights
​
(a)The authorized capital of Coherus as of the date hereof consists of: (i) 300,000,000 shares of Common Stock of which, as of January 23, 2021, (w) 72,681,383 shares were issued and outstanding, which excludes 1,833,640 shares of unvested restricted stock subject to repurchase, (x) 5,531,162 shares were available for future issuance pursuant to Coherus’s stock-based compensation plans, (y) 20,348,826 shares were issuable upon the exercise of stock options outstanding as of such date and (z) 16,416,023 shares were available  for were issuable upon exercise of outstanding convertible notes issued by Coherus, and (ii)
​

4

​

​
5,000,000 shares of Preferred Stock, of which no shares are issued and outstanding. All of the issued and outstanding shares of Common Stock (A) have been duly authorized and validly issued, (B) are fully paid and non-assessable and (C) were issued in compliance with all applicable federal and state securities laws and not in violation of any preemptive rights.
​
		(b)
	All of the authorized shares of Common Stock are entitled to one (1) vote per share.

​
(c)As of January 23, 2021, there were not any outstanding equity securities, options, warrants, rights (including conversion or preemptive rights) or other agreements pursuant to which Coherus is or may become obligated to issue, sell or repurchase any shares of its capital stock or any other securities of Coherus other than options granted pursuant to its stock-based compensation plans, which plans are described in the SEC Documents.
​
(d)Except pursuant to this Agreement or as described in this Section 2.7, Coherus is not a party to or subject to any agreement or understanding relating to (i) the voting of shares of capital stock of Coherus or the giving of written consents by a stockholder or director of Coherus, (ii) the issuance, sale, transfer or other disposition of or the repurchase, redemption or other acquisition of the equity interests of Coherus, (iii) any preemptive right, right of participation, right of maintenance, right of first refusal or any similar right with respect to equity interests of Coherus, (iv) the registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any equity interest of Coherus.
​
(e)Except for customary adjustments as a result of stock dividends, stock splits, combinations of shares, reorganizations, recapitalizations, reclassifications or other similar events, there are no anti-dilution or price adjustment provisions contained in any equity interest issued by Coherus and the issuance and sale of the Shares will not obligate Coherus to issue shares of Common Stock or other equity interests to any Person (other than Junshi) and will not result in a right of any holder of securities to adjust the exercise, conversion, exchange or reset price under any equity interests.
​
(f)To Coherus’ knowledge, except as set forth in the SEC Documents or any schedules filed with the SEC pursuant to Rule 13d-1 of the Exchange Act by reporting persons, no Person or group of related Persons “beneficially owns,” or has the right to acquire, by agreement with or by obligation binding upon Coherus, “beneficial ownership” of in excess of five percent (5%) of the outstanding Common Stock. For the purpose of this Section 2.7(f), (a) the terms “beneficial own” and “beneficially ownership” will have meanings correlative to that of “beneficial owner” as determined in accordance with Rule 13d-3 under the Exchange Act.
​
		2.8
	No Conflicts; Government Consents and Permits.

​
(a)The execution, delivery and performance of this Agreement by Coherus and the consummation by Coherus of the transactions contemplated hereby (including the issuance of the Shares) will not (i) conflict with or result in a violation of any provision of (a) Coherus’s Certificate of Incorporation or Bylaws or (b) any organizational documents of any of its subsidiaries, (ii) violate or conflict with, or result in a breach of any provision of or constitute
​

5

​

​
a default under, any agreement, indenture or instrument to which Coherus or any of its subsidiaries is a party or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including United States federal and state securities laws and regulations and regulations of any self-regulatory organizations) applicable to Coherus any of its subsidiaries, except in the case of clauses (i)(b), (ii) and (iii) only, for such conflicts, breaches, defaults and violations as would not reasonably be expected to be, have a Material Adverse Effect or result in a liability for Junshi.
​
(b)Coherus is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self regulatory agency in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms hereof, or to issue and sell the Shares in accordance with the terms hereof other than such as have been made or obtained, and except for (i) any post- signing filings required to be made under federal or state securities laws or (ii) any required filings or notifications regarding the issuance or listing of additional shares with Nasdaq.
​
2.9Litigation. Other than as set forth in the SEC Documents filed prior to the Execution Date, there is no action, suit, proceeding or investigation pending (of which Coherus has received notice or otherwise has knowledge) or, to Coherus’s knowledge, threatened, against Coherus or any of its subsidiaries or which Coherus or any of its subsidiaries intends to initiate, except where such action, suit, proceeding or investigation, as the case may be, would not reasonably be expected to have a Material Adverse Effect.
​
2.10Licenses and Other Rights; Compliance with Laws. Each of Coherus and its subsidiaries has all franchises, permits, licenses and other rights and privileges (“Permits”) necessary to permit it to own its properties and to conduct its business as presently conducted and is in compliance thereunder, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect. Neither Coherus nor any of its subsidiaries has taken any action that would interfere with its ability to renew all such Permit(s) when required, except where the failure to renew such Permit(s) would not reasonably be expected to have a Material Adverse Effect. Each of Coherus and its subsidiaries is and has been in compliance with all laws applicable to its business, properties and assets, except where the failure to be in compliance has not been and would not reasonably be expected to be, material to Coherus and its subsidiaries, taken as a whole.
​
		2.11
	Absence of Certain Changes.

​
(a)Except as disclosed in the SEC Documents filed prior to the Execution Date, since September 30, 2020, no change or event has occurred, except where such change or event has not and would not reasonably be expected to have a Material Adverse Effect.
​
(b)Except as set forth in the SEC Documents filed prior to the Execution  Date or as contemplated by this Agreement or the Collaboration Agreement, since September 30, 2020, Coherus has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, or (ii) sold, exchanged or otherwise disposed of any of its material assets or rights.
​

6

​

​
(c)Since September 30, 2020, neither Coherus nor any of its subsidiaries has (i) admitted in writing its inability to pay its debts generally as they become due, filed or consented to the filing against it of a petition in bankruptcy or a petition to take advantage of any insolvency act, made an assignment for the benefit of creditors, consented to the appointment of a receiver for itself or for the whole or any substantial part of its property, or had a petition in bankruptcy filed against it, been adjudicated bankrupt or filed a petition or answer seeking reorganization or arrangement under the federal bankruptcy laws or any other laws of the United States or any other jurisdiction, (ii) experienced any loss, damage or destruction to, or any interruption in the use of, any of the assets of Coherus or its such subsidiary (whether or not covered by insurance) or incurred any material liabilities other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice, and (B) liabilities not required to be reflected in Coherus’ financial statements pursuant to GAAP or required to be disclosed in filings made with the SEC, or (iii) altered its method of accounting or changed its auditors, except in the case of clauses (ii) and (iii) any such loss, damage, destruction, interruption or alteration that would not reasonably be expected to have a Material Adverse Effect.
​
2.12Not an Investment Company. Coherus is not, and solely after receipt of the Purchase Price, will not be, an “investment company” as defined in the Investment Company Act of 1940, as amended.
​
2.13No Integration. Coherus has not, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which is or will be integrated with the Shares sold pursuant to this Agreement in a manner that would require the registration of the Shares under the Securities Act.
​
2.14Transactions With Affiliates. Except as set forth in the SEC Documents filed prior to the Execution Date, none of the officers or directors of Coherus or any of its subsidiaries is presently a party to any transaction with Coherus or any of its subsidiaries (other than for ordinary course services as employees, officers or directors) that would be required to be reported on its Annual Report on Form 10-K.
​
2.15Manipulation of Price. Coherus has not, and to Coherus’ knowledge no one acting on its behalf has, since January 1, 2020 (a) taken, directly or indirectly, any action designed to cause or to result, or that would reasonably be expected to cause or result, in the stabilization or manipulation of the price of any security of Coherus to facilitate the sale or resale of any of the Shares, (b) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Shares, or (c) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of Coherus, in each case in violation of any federal or state securities law.
​
2.16Not a TID Business. Coherus is not, and will not immediately following the Closing be, a “TID business” as defined in 31 C.F.R. § 800.248.
​

7

​

​
Section 3. REPRESENTATIONS AND WARRANTIES OF JUNSHI
​
Except as otherwise specifically contemplated by this Agreement, Junshi hereby represents and warrants to Coherus that:
​
3.1Authorization; Enforcement. Subject to the receipt of the PRC Approvals, Junshi (a) has the requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, and (b) has taken all necessary corporate action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement, this Agreement will constitute a valid and binding obligation of Junshi enforceable against Junshi in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally, and except as enforceability may be subject to general principles of equity and except as rights to indemnity and contribution may be limited by state or federal securities laws or public policy underlying such laws.
​
		3.2
	No Conflicts; Government Consents and Permits.

​
(a)The execution, delivery and performance of this Agreement by Junshi and the consummation by Junshi of the transactions contemplated hereby (including the purchase of the Shares) will not (i) conflict with or result in a violation of any provision of Junshi’s articles of association, (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture or instrument to which Junshi is a party or (iii) result  in a violation of any law, rule, regulation, order, judgment or decree (including United States federal and state securities laws and regulations and regulations of any self-regulatory organizations) applicable to Junshi, except in the case of clauses (ii) and (iii) only, for such conflicts, breaches, defaults and violations as would not reasonably be expected to affect the ability of Junshi to consummate the transactions contemplated hereby or perform its obligations hereunder or result in a liability for Coherus.
​
(b)Junshi is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self regulatory agency in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms hereof, or to purchase the Shares in accordance with the terms hereof other than such as have been made or obtained, except for any consent required under the PRC Approvals.
​
3.3Investment Purpose. Junshi is purchasing the Shares for its own account and not with a present view toward the public distribution thereof and has no arrangement or understanding with any other persons regarding the distribution of the Shares. Junshi will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares except in accordance with the Securities Act and to the extent permitted by Section 6.1 and Section 6.2.
​
3.4Reliance on Exemptions. Junshi understands that Coherus intends for the Shares to be offered and sold to it in reliance upon specific exemptions from the registration
​

8

​

​
requirements of United States federal and state securities laws and that Coherus is relying upon the truth and accuracy of, and Junshi’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of Junshi set forth herein in order to determine the availability of such exemptions and the eligibility of Junshi to acquire the Shares.
​
3.5Accredited Investor; Access to Information. Junshi is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Junshi has been furnished with materials relating to the offer and sale of the Shares that have been requested by Junshi, including Coherus’s SEC Documents, and Junshi has had the opportunity to review the SEC Documents. Junshi has been afforded the opportunity to ask questions of Coherus.
​
3.6Brokers and Finders. No person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon Coherus for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of Junshi.
​
3.7Governmental Review. Junshi understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Shares or an investment therein.
​
Section 4. STANDSTILL AGREEMENT.
​
4.1Prior to the three (3) year anniversary of the Closing Date (the “Standstill Period”), Junshi and its Affiliates will not, directly or indirectly, except as expressly approved or invited by Coherus:
​
(a)effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in or in any way advise, assist or encourage any other person to effect or seek, offer or propose (whether publicly or otherwise) to effect or participate in, (i) any acquisition of any securities (or beneficial ownership thereof) or material assets of Coherus, (ii) any tender or exchange offer, merger or other business combination involving Coherus, (iii) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to Coherus or (iv) any “solicitation” of “proxies” (as such terms are used in the proxy rules of the SEC) or consents to vote any voting securities of Coherus;
​
(b)form, join or in any way participate in a “group” (as defined under the Exchange Act) with respect to any securities of Coherus;
​
(c)otherwise act, alone or in concert with others, to seek to control or influence the management, Board or policies of Coherus;
​
(d)take any action that would reasonably be expected to require Coherus to make a public announcement regarding any of the types of matters set forth in clause (a) above; or
​

9

​

​
(e)enter into any discussions or arrangements with any person with respect to any of the foregoing.
​
4.2Junshi also agrees during the Standstill Period not to request Coherus (or its representatives), directly or indirectly, to amend or waive any provision of this Section 4, other than by means of a confidential communication to the Coherus Chairman of the Board or Chief Executive Officer; provided that such communication will not require public disclosure. Junshi represents and warrants that, as of the Execution Date, neither Junshi nor any of its Affiliates owns, of record or beneficially, any voting securities of Coherus, or any securities convertible into or exercisable for any voting securities of Coherus.
​
4.3Notwithstanding the provisions set forth in Sections 4.1 and 4.2 (the “Standstill Provisions”), Junshi shall immediately, and without any other action by Coherus, be released from its obligations under the Standstill Provisions if: (a) Coherus executes a definitive agreement with a third party providing for an acquisition (by way of merger, tender offer or otherwise), of more than 50% of Coherus’s outstanding Common Stock or all or substantially all of Coherus’s assets or (b) a third party commences a tender offer seeking to acquire beneficial ownership of more than 50% of Coherus’s outstanding Common Stock and the Board recommends that the stockholders tender their Common Stock in such tender offer.
​
Section 5. VOTING AGREEMENT.
​
5.1If the Proxyholder instructs Junshi in writing to vote in favor of, or against, any matter, action, ratification or other event for which approval of the holders of Coherus’s stock is sought (either by vote or written consent) or upon which such holders are otherwise entitled to vote, including the election of directors, but excluding any Extraordinary Matter (collectively, a “Coherus Stockholder Matter”), then Junshi will (i) after receiving proper notice of any meeting of stockholders of Coherus related to such Coherus Stockholder Matter (or, if no notice is required or such notice is properly waived, after notice from the Proxyholder is given), be present, in person or by proxy, as a holder of Shares at all such meetings and be counted for the purposes of determining the presence of a quorum at such meetings and (ii) vote (in person, by proxy or by action by written consent, as applicable) all Shares as to which Junshi has beneficial ownership or as to which Junshi otherwise exercises voting or dispositive authority in the manner directed by the Proxyholder.
​
5.2Extraordinary Matters. Junshi may vote or execute a written consent with respect to, any or all of the voting securities of Coherus as to which they are entitled to vote or execute a written consent, as it may determine in its sole discretion, with respect to the following matters, if presented to Coherus’s stockholders for approval (each such matter being an “Extraordinary Matter”):
​
(i)any transaction which would result in a Change of Control of Coherus;
​
(ii)the payment of any dividends to any class of stockholders of Coherus;
​

10

​

​
(iii)any matter relating to or arising from the transactions contemplated by the Collaboration Agreement; or
​
		(iv)
	any liquidation or dissolution of Coherus.

​
5.3Appointment of Proxy. To secure Junshi’s obligations to vote the Shares in accordance with this Agreement and to comply with the other terms hereof, Junshi hereby appoints the Proxyholder, or his designees, as Junshi’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to vote or act by written consent with respect to all of Junshi’s Shares in accordance with the provisions set forth in this Agreement, and to execute all appropriate instruments consistent with this Agreement on behalf of Junshi. The proxy and power granted by Junshi pursuant to this Section 5 are coupled with an interest and are given to secure the performance of Junshi’s duties under this Agreement. Each such proxy and power will be irrevocable until the agreements contained in this Section 5expire in accordance with Section 5.5. The proxy and power will survive the merger, consolidation, conversion or reorganization of Junshi or any other entity holding any Shares (other than any Shares sold by Junshi in compliance with Section 6). For the avoidance of doubt, the proxy granted by this Section 5 shall not apply to any Extraordinary Matter.
​
5.4No Revocation. The voting agreements contained in this Section 5 are coupled with an interest and may not be revoked prior to their expiration in accordance with Section 5.5.
​
5.5Expiration. The agreements contained in this Section 5 will expire (i) in part, solely with respect to any Shares sold by Junshi in an arm’s length sale to a non-Affiliate in compliance with this Agreement upon the execution of the sale of such Shares, and (ii) as a whole on the earlier of (a) the three (3) year anniversary of the Closing Date and (b) the date the Collaboration Agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the Closing Date. For the avoidance of doubt, the agreements contained in this Section 5 shall not limit Junshi’s ability to transfer or resell any Shares, provided that such transfers or resales are done in accordance with Section 6.
​
Section 6. TRANSFER, RESALE, LEGENDS.
​
		6.1
	Transfer or Resale. Junshi understands that:

​
(a)the Shares have not been and are not being registered under the Securities Act or any applicable state securities laws and, consequently, Junshi may have to bear the risk of owning the Shares for an indefinite period of time because the Shares may not be transferred unless (i) the resale of the Shares is registered pursuant to an effective registration statement under the Securities Act; (ii) Junshi has delivered to Coherus an opinion of counsel (in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Shares to be sold or transferred may be sold or transferred pursuant to an exemption  from such registration; or (iii) the Shares are sold or transferred pursuant to Rule 144; and
​
(b)any sale of the Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and, if Rule 144 is not applicable, any resale of the Shares under circumstances in which the seller (or the person through whom the sale is made) may be
​

11

​

​
deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder.
​
6.2Lock-Up. Junshi agrees that it will hold and will not sell any of the Shares (or otherwise make any short sale of, grant any option for the purchase of or enter into any hedging or similar transaction with the same economic effect as a sale of the Shares) until the earlier of (a) the day following the two (2) year anniversary of the Closing Date and (b) the date the Collaboration Agreement is terminated (the “Holding Period”). In addition, after the expiration of the Holding Period, in any single trading day Junshi will not (i) sell an amount of Shares that exceeds 5% of the average daily trading volume of the Common Stock on Nasdaq over the five (5) trading day period ending on the trading day immediately prior to such trading date (the “Volume Limitation”) or (ii) knowingly sell, and will instruct its broker not to sell, any Shares to a Competitor (unless the identity of the purchaser is not known to Junshi or the broker). Notwithstanding the foregoing, this Section 6.2 will not preclude, and the Volume Limitation shall not apply to, sales of Shares by Junshi to a third party pursuant to a tender offer made by such third party.
​
6.3Legends. Junshi understands the Shares will bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the Shares):
​
THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.
​
THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.
​
If such Shares may be transferred pursuant to Section 6.2, Junshi may request that Coherus remove, and Coherus agrees to authorize and instruct (including by causing any required legal opinion to be provided) the removal of any legend from the Shares, if permitted by applicable securities law, within two (2) Business Days of any such request; provided, however, each party will be responsible for any fees it incurs in connection with such request and removal.
​
Section 7. CONDITIONS TO CLOSING
​
7.1Conditions to Obligations of Coherus. Coherus’s obligation to complete the purchase and sale of the Shares and deliver the Shares to Junshi is subject to the fulfillment or waiver of the following conditions at or prior to the Closing:
​
(a)Representations and Warranties. The representations and warranties made by Junshi in Section 3 will be true and correct in all material respects as of the Closing Date,
​

12

​

​
except to the extent such representations and warranties are made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date.
​
(b)Covenants. All covenants and agreements contained in this Agreement to be performed or complied with by Junshi on or prior to the Closing Date shall have been performed or complied with in all material respects.
​
(c)Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any court, arbitrator, governmental body, agency or official.
​
(d)No Governmental Prohibition. The sale of the Shares by Coherus and the purchase of the Shares by Junshi will not be prohibited by any applicable law or governmental order or regulation or by any Governmental Authority.
​
		(e)
	PRC Approvals. The PRC Approvals shall have been obtained and shall remain valid.

​
(f)Collaboration Agreement. Junshi shall have duly executed and delivered the Collaboration Agreement to Coherus, and subject to execution by Junshi, such agreement shall be in full force and effect pursuant to its terms.
​
(g)Closing Deliverables. All  closing  deliverables  as  required  under Section 1.3(b) shall have been delivered by Junshi to Coherus.
​
7.2Conditions to Junshi’s Obligations at the Closing. Junshi’s obligation to complete the purchase and sale of the Shares is subject to the fulfillment or waiver of the following conditions at or prior to the Closing:
​
(a)Representations and Warranties. The representations and warranties made by Coherus in Section 2 will be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date.
​
(b)Covenants. All covenants and agreements contained in this Agreement to be performed or complied with by Coherus on or prior to the Closing Date shall have been performed or complied with in all material respects.
​
(c)Transfer Agent Instructions. Coherus will have delivered to its transfer agent irrevocable written instructions to issue the Shares to Junshi in a form and substance acceptable to such transfer agent.
​
(d)Nasdaq Qualification. The Shares will be duly authorized for listing by Nasdaq, subject to official notice of issuance.
​

13

​

​
(e)Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any court, arbitrator, governmental body, agency or official.
​
		(f)
	PRC Approvals. The PRC Approvals shall have been obtained and shall remain valid.

​
(g)Collaboration Agreement. Coherus shall have duly executed and delivered the Collaboration Agreement to Junshi, and subject to execution by Coherus, (i) such agreement shall be in full force and effect pursuant to its terms, and (ii) the Upfront Payment (as defined in the Collaboration Agreement) shall have been fully paid by Coherus pursuant to its terms.
​
(h)No Governmental Prohibition. The sale of the Shares by Coherus, and the purchase of the Shares by Junshi will not be prohibited by any applicable law or governmental order or regulation or by any Governmental Authority.
​
(i)Closing Deliverables. All  closing  deliverables  as  required  under Section 1.3(b) shall have been delivered by Coherus to Junshi.
​
Section 8. TERMINATION.
​
		8.1
	Ability to Terminate. This Agreement may be terminated:

​
		(a)
	at any time by mutual written consent of Coherus and Junshi;

​
(b)by Coherus, upon written notice to Junshi, so long as Coherus is not then in breach of its representations, warranties, covenants or agreements under this Agreement such that any of the conditions set forth in Section 7.1, as applicable, could not be satisfied by the Termination Date, (i) upon a breach of any covenant or agreement on the part of Junshi set forth in this Agreement or (ii) if any representation or warranty of Junshi shall have been or become untrue, in each case such that any of the conditions set forth in Section 7.1 could not be satisfied by the Termination Date;
​
(c)by Junshi, upon written notice to Coherus, so long as Junshi is not then in breach of its representations, warranties, covenants or agreements under this Agreement such that any of the conditions set forth in Section 7.2, as applicable, could not be satisfied by the Termination Date, (i) upon a breach of any covenant or agreement on the part of Coherus set forth in this Agreement, or (ii) if any representation or warranty of Coherus shall have been or become untrue, in each case such that any of the conditions set forth in Section 7.2 could not be satisfied by the Termination Date.
​
(d)by either Coherus or Junshi, upon written notice to the other, if the Closing has not occurred on or before the date six (6) months after the Execution Date (the “Termination Date”). In such event, neither party shall have any further obligations under this Agreement.
​

14

​

​
8.2Automatic Termination. In the event that the Collaboration Agreement is terminated prior to the Closing Date, this Agreement shall terminate automatically.
​
8.3Effect of Termination. In the event of the termination of this Agreement pursuant to Section 8.1 or Section 8.2, (a) this Agreement (except for this Section 8.3 and Section 9, and any definitions set forth in this Agreement and used in such Sections) shall forthwith become void and have no effect, without any liability on the part of any party hereto or its Affiliates, and (b) all filings, applications and other submissions made pursuant to this Agreement, to the extent practicable, shall be withdrawn from the agency or other person to which they were made or appropriately amended to reflect the termination of the transactions contemplated hereby; provided, however, that nothing contained in this Section 8.3 shall relieve any party from liability for fraud or any intentional or willful breach of this Agreement.
​
Section 9. GOVERNING LAW; MISCELLANEOUS.
​
9.1Governing Law; Jurisdiction. This Agreement will be governed by and interpreted in accordance with the laws of the State of Delaware without regard to the principles of conflict of laws.
​
9.2Market Listing. Coherus shall use reasonable best efforts to (a) maintain the listing and trading of the Common Stock on Nasdaq and (b) effect the listing of the Shares on Nasdaq.
​
9.3CFIUS. Notwithstanding anything to the contrary in this Agreement, the Collaboration Agreement or any other agreement between the parties, Junshi shall neither be permitted nor seek (a) control rights (as defined in 31 C.F.R. § 800.208) in respect of Coherus or any Coherus subsidiary; (b) membership or observer rights on, or the right to nominate an individual to a position on, the Board or equivalent governing body of any Coherus subsidiary; (c) access to any material nonpublic technical information (as defined at 31 C.F.R. § 800.232) in the possession of Coherus or any Coherus subsidiary; or (d) any involvement, other than through voting of shares, in substantive decision making of Coherus or any Coherus subsidiary regarding: (i) the use, development, acquisition, safekeeping, or release of sensitive personal data of U.S. citizens (as defined at 31 C.F.R. § 800.241) maintained or collected by Coherus or any Coherus subsidiary; (ii) the use, development, acquisition, or release of critical technologies (as defined at 31 C.F.R. § 800.215); or (iii) the management, operation, manufacture, or supply of covered critical infrastructure, in each case of (b)-(d), within the meaning of 31 C.F.R. § 800.211(b). Junshi hereby waives any such rights to which it may be entitled under this Agreement, the Collaboration Agreement or any other agreement between the parties or otherwise, including any statutory rights to such information as a stockholder of Coherus.
​
9.4PRC Approvals. Junshi shall, (a) as promptly as practicable following the date hereof (but in any event within ten (10) Business Days after the date of this Agreement), file all documentation necessary to be filed with MOFCOM and NDRC in connection with the PRC Approvals, and (b) within five (5) Business Days after Junshi obtains the necessary approval from MOFCOM and NDRC (whichever is later) in connection with the PRC Approvals, file the documentation necessary to be filed with a bank designated to handle the foreign exchange
​

15

​

​
affairs for the transaction contemplated hereunder in connection with the PRC Approval by SAFE. Junshi shall (i) use its reasonable best efforts to take all actions required by law and otherwise reasonably necessary to obtain the PRC Approvals as promptly as practicable; (ii) provide Coherus with reasonable opportunity to review and comment on any written submissions, which comments will be considered in good faith; and (iii) keep Coherus reasonably apprised of the status of inquiries from, and communications with, any Governmental Authority with respect to the PRC Approvals.
​
9.5Counterparts; Electronic Signatures. This Agreement may be executed in two counterparts, both of which are considered one and the same agreement and will become effective when the counterparts have been signed by each party and delivered to the other party hereto. This Agreement, once executed by a party, may be delivered to the other party hereto by electronic PDF of a copy of this Agreement bearing the signature of the party so delivering this Agreement.
​
9.6Headings. The headings of this Agreement are for convenience of reference  only, are not part of this Agreement and do not affect its interpretation.
​
9.7Severability. If any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the parties will negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the parties and all other provisions hereof will remain in full force and effect in such jurisdiction and will be liberally construed in order to carry out the intentions of the parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability will not affect the validity, legality or enforceability of such provision in any other jurisdiction.
​
9.8Entire Agreement; Amendments. This Agreement (including any schedules  and exhibits hereto) and the Collaboration Agreement constitute the entire agreement between the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein or therein. This Agreement (including any schedules and exhibits hereto) and the Collaboration Agreement supersede all prior agreements and understandings between the parties hereto with respect to the subject matter hereof. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the party to be charged with enforcement. Any amendment or waiver effected in accordance with this Section 9.8 will be binding upon Junshi and Coherus.
​
9.9Notices. All notices required or permitted hereunder will be in writing and will  be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed email if sent during normal business hours of the recipient, if not, then on the next Business Day, or (c) one Business Day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. The addresses for such communications are:
​

16

​

​
If to Coherus, addressed to:Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065 
Attention: Chief Executive Officer 
E-mail: DML152@coherus.com
​
with a copy to:Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600 
Redwood City, CA 94065 
Attention: Chief Legal Officer
E-mail: tfitzpatrick@coherus.com
​
Ropes & Gray LLP 
800 Boylston Street 
Prudential Tower
Boston, Massachusetts 02199 
Attention: Zachary R. Blume
E-mail: Zachary.Blume@ropesgray.com
​
If to Junshi, addressed to:Shanghai Junshi Biosciences Co., Ltd.
Level 13, Building 2, Nos. 36 and 58, Hai Qu Road
Shanghai, China 201203 
Attention: CEO
​
And to:Shanghai Junshi Biosciences Co., Ltd.
Level 13, Building 2, Nos. 36 and 58, Hai Qu Road
Shanghai, China 201203
Attention: Board Secretary, Securities Department
​
with a copy to:Jones Day
51 Louisiana Avenue, N.W. 
Washington, DC 20001 
Attention: Daniel J. Michaels
E-mail: dmichaels@jonesday.com
​
9.10Successors and Assigns. This Agreement is binding upon and inures to the benefit of the parties and their successors and assigns. Coherus will not assign this Agreement or any rights or obligations hereunder without the prior written consent of Junshi, and Junshi will not assign this Agreement or any rights or obligations hereunder without the prior written consent of Coherus; provided, however, that Junshi may assign this Agreement together with all of the Shares it then owns (subject to Section 4, Section 5 and Section 6) to any wholly-owned subsidiary and any such assignee may assign the Agreement together with all of the Shares it then owns (subject to Section 4, Section 5 and Section 6) to Junshi or any other subsidiary wholly-owned by Junshi, in any such case, without such consent provided that the assignee agrees to assume Junshi’s obligations under Section 4, Section 5 and Section 6 of this Agreement.

17

​

​
9.11Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto, their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.
​
9.12Further Assurances; Survival. Each party will do and perform, or cause to be done and performed, all such further acts and things, and will execute and deliver all other agreements, certificates, instruments and documents, as the other party may reasonably request  in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. The provisions of this Agreement will survive termination.
​
9.13No Strict Construction. The language used in this Agreement is deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against a party.
​
9.14Equitable Relief. Coherus recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to Junshi. Coherus therefore agrees that Junshi is entitled to seek temporary and permanent injunctive relief or specific performance in any such case. Junshi also recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to Coherus. Junshi therefore agrees that Coherus is entitled to seek temporary and permanent injunctive relief or specific performance in any such case.
​
9.15Expenses. Coherus and Junshi are each liable for, and will pay, their own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement, including attorneys’ and consultants’ fees and expenses.
​
[Remainder of page intentionally left blank.]
​
​

18

​

​
IN WITNESS WHEREOF, Junshi and Coherus have caused this Agreement to be duly executed as of the date first above written.
​
	​

	​

	​

	​
	COHERUS BIOSCIENCES, INC.

	​
	​

	​
	​

	​
	By:
	/s/ Dennis M. Lanfear

	​
	Name:
	Dennis M. Lanfear

	​
	Title:
	Chairman & Chief Executive

	​
	​
	​

	​
	​
	​

	​
	SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

	​
	​

	​
	​

	​
	By:
	​

	​
	Name:
	​

	​
	Title:
	​

​
​

[Signature page to Stock Purchase Agreement]

​

​
IN WITNESS WHEREOF, Junshi and Coherus have caused this Agreement to be duly executed as of the date first above written.
​
	​

	​

	​

	​
	COHERUS BIOSCIENCES, INC.

	​
	​

	​
	​

	​
	By:
	​

	​
	Name:
	​

	​
	Title:
	​

	​
	​
	​

	​
	​
	​

	​
	SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

	​
	​

	​
	​

	​
	By:
	/s/ Ning Li

	​
	Name:
	Ning Li

	​
	Title:
	CEO

​
​

[Signature page to Stock Purchase Agreement]

​

​
APPENDIX 1
​
DEFINED TERMS
​
“Affiliate” means with respect to any Person, any Person controlling, controlled by or under common control with such first Person. For purposes of this definition, “control” means (a) direct or indirect ownership of fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of such Person (or if the jurisdiction where such Person is domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted under such laws; provided, that such ownership interest provides actual control over such Person), (b) status as a general partner in any partnership or (c) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise.
​
“Board” means the board of directors of Coherus.
​
“Business Day” means any day other than a Saturday or a Sunday on which the banks in New York, New York, Shanghai, the PRC and the Hong Kong Special Administrative Region are open for business.
​
“Change of Control” means, with respect to a party, any of the following events occurring after the Closing Date: (a) any “person” or “group” (as such terms are defined below) (i) is or becomes the “beneficial owner” (as defined below), directly or indirectly, of shares of capital stock or other interests (including partnership interests) of such party then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar supervisory positions (“Voting Stock”) of such party representing fifty percent (50%) or more of the total voting power of all outstanding classes of Voting Stock of such party or (ii) has the power, directly or indirectly, to elect a majority of the members of the party’s board of directors, or similar governing body; (b) such party enters into a merger, consolidation or similar transaction with another person (whether or not such party is the surviving entity), and as a result of such merger, consolidation or similar transaction (i) the members of the board of directors of such party immediately prior to such transaction constitute less than a majority of the members of the board of directors of such party or such surviving Person immediately following such transaction or (ii) the Persons that beneficially owned, directly or indirectly, the shares of Voting Stock of such party immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of such party representing at least a majority of the total voting power of all outstanding classes of Voting Stock of the surviving Person or the ultimate parent entity of such surviving Person in substantially the same proportions as their ownership of Voting Stock of such party immediately prior to such transaction; (c) such party sells or transfers to any third party, in one (1) or more related transactions, properties or assets representing all or substantially all of such party’s consolidated total assets; or (d) the holders of capital stock of such party approve a plan or proposal for the liquidation or dissolution of such party. For the purpose of this definition of Change of Control: (a) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the Exchange Act and the term “group” includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the exchange Act; (b) a “beneficial owner” will be determined in accordance with Rule
​

20

​

​
13d-3 under the Exchange Act; and (c) the terms “beneficially owned” and “beneficially own” will have meanings correlative to that of “beneficial owner.”
​
“Closing Date” means the date on which the Closing actually occurs.
​
“Coherus’ knowledge” means the actual knowledge of Coherus’s Chief Executive Officer or Chief Financial Officer.
​
“Collaboration Agreement” means that certain Exclusive License and Commercialization Agreement, dated February 1, 2021, by and between Coherus and Junshi.
​
“Common Stock” means shares of Coherus’s common stock, par value $0.0001 per share.
​
“Competitor” means any operating company with a biopharmaceutical business, or any other Person that directly or indirectly beneficially owns a majority of the voting securities of or voting interests in such a company, or any direct or indirect majority-owned subsidiary of such a company or of such a Person.
​
“DOJ” means the U.S. Department of Justice.
​
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC thereunder.
​
“FTC” means the United States Federal Trade Commission or any successor agency thereto.
​
“GAAP” means generally accepted accounting principles in the United States of America as applied by Coherus.
​
“Governmental Authority” means any multinational, federal, national, state, provincial, local or other entity, office, commission, bureau, agency, political subdivision, instrumentality, branch, department, authority, board, court, arbitral or other tribunal, official or officer, exercising executive, judicial, legislative, police, regulatory, administrative or taxing authority or functions of any nature pertaining to government and including any stock exchange on which the shares of Coherus or Junshi are listed.
​
“Lien” means any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction.
​
“Material Adverse Effect” means any change, effect or circumstance, individually or in the aggregate, (a) the business, properties or financial condition of Coherus and its subsidiaries on a consolidated basis, or (b) Coherus’s ability to issue the Shares hereunder; provided that none of the following shall be taken into account in determining whether there is a Material Adverse Effect: (i) any change in the market price or trading volume of Coherus’s stock; (ii) any event, circumstance, change or effect in the industries in which Coherus or its subsidiaries operates or the United States or European economy generally, in financial markets or in political conditions generally; (iii) any act of terrorism, military action or war (whether or not declared), national or international calamity or similar event, any natural disasters, acts of God or comparable events,
​

21

​

​
epidemic, pandemic or disease outbreak (including the COVID-19 virus), or any escalation or worsening thereof; (iv) any event, circumstance, change or effect arising from or relating to any change in legal requirements or GAAP (or interpretations of any legal requirements thereof);
(v) any study results from clinical trials or preclinical/non-clinical trials of Coherus’s drug candidates; or (vi) any change or effect attributable to the consummation of the transactions contemplated hereby, or the public announcement of the execution of, this Agreement (provided any such public announcement is not in breach of this Agreement or the Collaboration Agreement); provided, further that the exceptions set forth in clauses (i)-(iv) shall only apply to the extent that the effect of the event, circumstance, change or effect is not disproportionately more adverse to Coherus and its subsidiaries in any material respect, taken as a whole, than the effect of the change on comparable businesses or companies in the industry in which Coherus and its subsidiaries operate.
​
“MOFCOM” means the Ministry of Commerce of the PRC or its competent local counterparts.
​
“Nasdaq” means The Nasdaq Global Select Market.
​
“NDRC” means the National Development and Reform Commission of the PRC or its competent local counterparts.
​
“Person” means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship or other business organization or a Governmental Authority.
​
“PRC” means the People’s Republic of China, but solely for purposes of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the Islands of Taiwan.
​
“PRC Approvals” means (a) the issuance of a certificate of outbound investment by enterprises by MOFCOM, (b) the approval by NDRC pursuant to the Measures for the Administration of Overseas Investment of Enterprises (Order of the National Development and Reform Commission (No. 11)) (《企业境外投资管理办法》(国家发展和改革委员会令第11号)),
(c) the approval or consent by SAFE, and pursuant to any other applicable PRC laws and
regulations, in each case of (a)-(c), with respect to the transactions contemplated hereby.
​
“Preferred Stock” means shares of Coherus’s preferred stock, par value $0.0001 per share.
​
“Proxyholder” means Coherus and its Chief Executive Officer in his capacity as an officer of Coherus.
​
“SAFE” means the State Administration of Foreign Exchange of the PRC (or its competent local counterparts).
​
“SEC” means the United States Securities and Exchange Commission or any successor entity.
​
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations of the SEC thereunder.

22EX-10.1

 Exhibit 10.1 

AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

DATED AS OF [                ], 2021 

AMONG 
 TASKUS, INC.

 AND 
 THE OTHER
PARTIES HERETO 
  

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	ARTICLE I REPRESENTATIONS AND WARRANTIES OF THE PARTIES	  	 	1	 
	          	 	1.1	  	Representations and Warranties of the Company	  	 	1	 
		 	1.2	  	Representations and Warranties of the Stockholders	  	 	1	 
	ARTICLE II GOVERNANCE	  	 	2	 
		 	2.1	  	Board of Directors	  	 	2	 
		 	2.2	  	Matters Requiring Approval	  	 	5	 
		 	2.3	  	Trust Arrangements	  	 	6	 
		 	2.4	  	Founder Group Actions	  	 	6	 
	ARTICLE III TRANSFERS OF SECURITIES	  	 	6	 
		 	3.1	  	Restrictions on Transfer of Non-Blackstone Securities	  	 	6	 
		 	3.2	  	Securities Act Compliance	  	 	6	 
		 	3.3	  	Certain Transferees Bound by Agreement	  	 	7	 
		 	3.4	  	Transfers in Violation of Agreement	  	 	7	 
	ARTICLE IV ADDITIONAL COVENANTS	  	 	7	 
		 	4.1	  	Pledges or Transfers	  	 	7	 
		 	4.2	  	Spin-Offs or Split-Offs	  	 	7	 
	ARTICLE V INFORMATION; VCOC	  	 	8	 
		 	5.1	  	Books and Records; Access	  	 	8	 
		 	5.2	  	Tax Related Information	  	 	8	 
		 	5.3	  	Certain Reports	  	 	8	 
		 	5.4	  	VCOC	  	 	8	 
		 	5.5	  	Information Sharing	  	 	11	 
	ARTICLE VI AMENDMENT AND TERMINATION	  	 	11	 
		 	6.1	  	Amendment and Waiver	  	 	11	 
		 	6.2	  	Termination of Agreement	  	 	11	 
		 	6.3	  	Termination as to a Party	  	 	12	 
	ARTICLE VII MISCELLANEOUS	  	 	12	 
		 	7.1	  	Certain Defined Terms	  	 	12	 
		 	7.2	  	Legends	  	 	16	 
		 	7.3	  	Non-Compete	  	 	17	 
		 	7.4	  	Confidentiality	  	 	18	 
		 	7.5	  	Severability	  	 	19	 
		 	7.6	  	Entire Agreement	  	 	19	 
		 	7.7	  	Successors and Assigns	  	 	20	 

  
 i 

									
		 	7.8	  	Counterparts	  	 	20	 
	          	 	7.9	  	Remedies	  	 	20	 
		 	7.10	  	Notices	  	 	20	 
		 	7.11	  	Governing Law	  	 	21	 
		 	7.12	  	Descriptive Headings	  	 	21	 
		 	7.13	  	Grant of Consent	  	 	22	 

  
 ii 

 AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

This Amended and Restated Stockholders Agreement (this “Agreement”) is entered into as of
[                ], 2021 by and among TaskUs, Inc. (formerly known as TU TopCo, Inc.), a Delaware corporation (the “Company”), BCP FC Aggregator LP
(“Sponsor” and, together with its Affiliates and transferees who acquire securities from time to time, the “Blackstone Holders”), parties to this Agreement who are identified as
Non-Blackstone Holders on the signature pages hereto (each, a “Non-Blackstone Holder” and, collectively, the
“Non-Blackstone Holders”), Bryce Maddock and Jaspar Weir (each, a “Founder” and, collectively, the “Founders”) and each other holder of Securities who
hereafter executes a separate joinder agreement to be bound by the terms hereof (the Blackstone Holders, the Non-Blackstone Holders and each other Person that is or becomes a party to this Agreement as
contemplated hereby are sometimes referred to herein collectively as the “Stockholders” and individually as a “Stockholder”). Certain capitalized terms used herein are defined in
Section 7.1. 
 The parties hereto agree as follows: 

ARTICLE I 
 REPRESENTATIONS AND
WARRANTIES OF THE PARTIES 
 1.1    Representations and Warranties of the Company. The Company hereby represents
and warrants to the Stockholders that as of the date of this Agreement: 
 (a)    it is a corporation,
validly existing and in good standing under the laws of the State of Delaware, it has full power and authority to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby, and the execution, delivery and
performance by it of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action; 

(b)    this Agreement has been duly and validly executed and delivered by the Company and constitutes a
legal and binding obligation of the Company, enforceable against the Company in accordance with its terms; and 

(c)    the execution, delivery and performance by the Company of this Agreement and the consummation by the
Company of the transactions contemplated hereby will not, with or without the giving of notice or lapse of time, or both, (i) violate any provision of law, statute, rule or regulation to which the Company is subject, (ii) violate any
order, judgment or decree applicable to the Company, or (iii) conflict with, or result in a breach or default under, any term or condition of the Company’s Organizational Documents or any agreement or instrument to which the Company is a
party or by which it is bound. 

 1.2    Representations and Warranties of the Stockholders. Each
Stockholder (as to such Stockholder only) represents and warrants to the Company and the other Stockholders that, as of the time such Stockholder becomes a party to this Agreement: 

(a)    this Agreement (or the separate joinder agreement executed by such Stockholder) has been duly and
validly executed and delivered by such Stockholder, and this Agreement constitutes a legal and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms; and 

(b)    the execution, delivery and performance by such Stockholder of this Agreement (or any joinder to
this Agreement) and the consummation by such Stockholder of the transactions contemplated hereby (and thereby) will not, with or without the giving of notice or lapse of time, or both, (i) violate any provision of law, statute, rule or
regulation to which such Stockholder is subject, (ii) violate any order, judgment or decree applicable to such Stockholder, or (iii) conflict with, or result in a breach or default under, any term or condition of any agreement or other
instrument to which such Stockholder is a party or by which such Stockholder is bound. 
 ARTICLE II 

GOVERNANCE 

2.1    Board of Directors. 

(a)    Board Size. The size of the Board shall initially be six (6) directors and the Board as of the date of
this Agreement is comprised of Amit Dixit, Susir Kumar, Mukesh Mehta, Jacqueline Reses, Bryce Maddock and Jaspar Weir; provided that the size of the Board may be increased or decreased by a majority vote of the Board, but subject to
Section 2.1(b)(i)(B). The Company, the Stockholders and the Board shall take all necessary action to cause the Board to be composed as set forth in this Section 2.1. 

(b)    Board Representation. 

(i)    Each Stockholder agrees that it shall vote, or execute a written consent in lieu thereof with
respect to all of the Securities beneficially owned or held of record by it or cause all of the Securities beneficially owned by it to be voted, or cause a written consent in lieu thereof to be executed, to elect a Board to be composed as follows:

 (A)    Subject to Section 2.1(b)(ii) and (v), for so long as a
Founder Group meets the Founder Group Minimum Ownership Condition, such Founder Group shall be entitled to designate one (1) director (each, a “Founder Designee”); provided that if (x) neither Founder Group
meets the Founder Group Minimum Ownership Condition individually, but collectively, both Founder Groups Beneficially Own, in the aggregate, a number of Securities representing an Ownership Percentage of at least 5% and (y) neither Founder Group
has made any Transfer other than Transfers to the Permitted Group of the Founder who is associated with such Founder Group then the Founder Groups (collectively) shall be entitled to designate one (1) director (a “Joint Founder
Designee”), provided, further, that, if one Founder Group has made any Transfer other than Transfers to the Permitted Group of the Founder who is associated with such Founder Group but the other Founder Group has not, and the
condition in clause (x) of the preceding proviso has been met, then the condition in clause (y) of the preceding 

  
 2 

 
proviso will be deemed to have been met and the Founder whose Founder Group has not made any Transfer other than Transfers to the Permitted Group of such Founder shall be entitled to designate
such Joint Founder Designee; and 
 (B)    The Sponsor shall have the right, but not the obligation, to
designate, and the individuals nominated for election as directors by or at the direction of the Board or a duly authorized committee of the Board shall include, a number of individuals such that, upon the election of each such individual, and each
other individual nominated by or at the direction of the Board or a duly authorized committee of the Board, as a director of the Company and taking into account any director continuing to serve without the need for
re-election, the number of Blackstone Designees (as defined below) serving as directors of the Company will be equal to: (i) if the Sponsor and its affiliates collectively Beneficially Own 50% or more of
the Common Stock as of the record date for such meeting, the lowest whole number that is greater than 50% of the Total Number of Directors; (ii) if the Sponsor and its Affiliates collectively Beneficially Own at least 40% (but less than 50%) of
the Common Stock as of the record date for such meeting, the lowest whole number that is greater than 40% of the Total Number of Directors; (iii) if the Sponsor and its Affiliates collectively Beneficially Own at least 30% (but less than 40%)
of the Common Stock as of the record date for such meeting, the lowest whole number that is greater than 30% of the Total Number of Directors; (iv) if the Sponsor and its Affiliates collectively Beneficially Own at least 20% (but less than 30%)
of the Common Stock as of the record date for such meeting, the lowest whole number that is greater than 20% of the Total Number of Directors; and (v) if the Sponsor and its Affiliates collectively Beneficially Own at least 5% (but less than
20%) of the Common Stock as of the record date for such meeting, the lowest whole number (such number always being equal to or greater than one) that is greater than 10% of the Total Number of Directors (in each case, each such person a
“Blackstone Designee”). 
 (each director so designated by a Founder Group or Sponsor, a “Designee”);
provided that if a Founder Group is entitled to only one Designee, such Designee shall be the applicable Founder of such Founder Group unless such Founder cannot serve on the Board due to death or disability; provided, further,
that in the event a Founder Group is entitled to one Designee but the applicable Founder of such Founder Group cannot serve on the Board due to death or disability, such Designee shall be chosen by the other Founder, which individual must have
relevant industry experience and such surviving Founder shall consult with the Blackstone Designees prior to choosing such Designee; provided, further, in the event both Founder Groups are entitled to each designate one Designee but
both Founders are unable to serve on the Board due to death or disability, each such Designee shall be chosen by their respective Founder Groups, which individual must have industry experience and be reasonably acceptable to the Blackstone Designees
(such approval shall not be unreasonably withheld, conditioned or delayed). 

  
 3 

 (ii)    Subject to
Section 2.1(b)(i)(A), if at any time a Founder Group fails to meet the Founder Group Minimum Ownership Condition, then such Founder Group’s right to designate, nominate and replace any member of the Board (other than a
Joint Founder Designee, if applicable) shall terminate and reduce to zero (0) directors, and such Founder Group agrees to promptly thereafter cause its Designee director to tender his or her immediate resignation from the Board. 

(iii)    In the event that a vacancy is created on the Board at any time by the death, disability,
retirement, resignation or removal of any Designee director, only the Founder Group or Stockholder that designated such deceased, disabled, retired, resigning or removed Designee may designate another individual (the “Replacement
Nominee”) to fill such vacancy and serve as a director on the Board and each Stockholder agrees that it shall vote, or execute a written consent in lieu thereof with respect to all of the Securities beneficially owned or held of record by
it or cause all of the Securities beneficially owned by it to be voted, or cause a written consent in lieu thereof to be executed to elect such Replacement Nominee to the Board. 

(iv)    Directors are subject to removal pursuant to the applicable provisions of the Certificate of
Incorporation of the Company; provided, however, for as long as this Agreement remains in effect, (x) the Blackstone Designees may only be removed with the consent of the Sponsor, (y) each Founder Designee may only be removed
with the consent of the applicable Founder Group that designated such Founder Designee and (z) the Joint Founder Designee may only be removed with the consent of both Founder Groups, in each case delivered in accordance with
Section 7.13 hereof. 
 (c)    Quorum; Majority Vote. Notice of the time and place of
all meetings of the Board shall be given to all members of the Board at least forty-eight (48) hours before the date and time of the meeting; except that shorter reasonable notice may be given for matters outside the ordinary course of business
requiring urgent attention from the Board as determined in good faith by the Board and to the extent such shorter notice is approved or ratified by the Board at such meeting. The members of the Board shall be entitled to participate in any such
meeting by conference telephone or other communications equipment. A quorum of the Board shall consist of a majority of the members of the Board and the presence of at least two (2) Blackstone Designees. Except as otherwise provided herein, the
affirmative vote of a majority of the directors of the Board present at a meeting for which there is a quorum shall be the act of the Board. 

(d)    Certificate of Incorporation and By-law Provisions. Each Stockholder
shall vote all of its Securities that are entitled to vote or execute proxies or written consents, as the case may be, and take all other actions necessary, to ensure that the Certificate of Incorporation and
By-laws of the Company facilitate, and do not at any time conflict with, any provision of this Agreement. 

(e)    D&O Insurance. The Company shall maintain, from financially sound and reputable insurers, Directors and
Officers liability insurance, in an amount and on terms and conditions satisfactory to the Board, for the benefit of all directors on equivalent terms, and will use commercially reasonable efforts to cause such insurance policy to be maintained
until such time as the Board determines that such insurance should be discontinued. 

  
 4 

 (f)    Indemnification. The Company’s Certificate of
Incorporation and Bylaws shall provide (i) for elimination of the liability of directors to the maximum extent permitted by law and (ii) for indemnification of directors for acts on behalf of the Company to the maximum extent permitted by
law. In addition, the Company shall enter into and use its commercially reasonable efforts to at all times maintain indemnification agreements with the Founder Group Designees, which agreements shall be no less favorable to such Founder Group
Designees as those entered into with the Blackstone Designees. 
 (g)    Successor Indemnification. If the
Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be
made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the
Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 2.2    Matters
Requiring Approval. Notwithstanding any provision of this Agreement to the contrary, for so long as the Sponsor and its Affiliates and the Founders and their Affiliates, respectively, collectively Beneficially Own at least 5% of the then
outstanding shares of Common Stock and are entitled to designate at least one director of the Company pursuant to Section 2.1(b) (or such earlier date that the Sponsor or the Founders request their respective approval
rights to be terminated), the Company shall not take, and shall cause its Subsidiaries not to take, any of the following actions without the prior written consent of the Sponsor and at least one of the Founders: 

(a)    Enter into any related party agreement or transaction between the Company or any of its
Subsidiaries, on the one hand, and the Sponsor or any of its Affiliates (including the payment of any management, investment banking or similar fees to Sponsor or any Affiliate of Sponsor) or one of the Founders and his Affiliates, on the other
hand, other than (i) in connection with any Rescue Financing, which shall be subject to the approval of the Board; or (ii) transactions or agreements which are on arms’ length terms entered into by the Company or any of its
Subsidiaries in the ordinary course of business with a portfolio company of Sponsor or a portfolio company of any Affiliate of Sponsor; 

(b)    Other than Excepted Issuances, issue, grant, award or issue rights to subscribe for, exchange or
convert into, any Securities or New Securities of the Company or any of its Subsidiaries; 

(c)    Declare or pay any Distribution, other than (i) Distributions by the Company’s
Subsidiaries that are paid pro rata to the Subsidiaries’ shareholders; and (ii) Distributions in respect of the Securities offered or paid pro-rata to the Stockholders or otherwise pursuant to the
terms of the Company’s Organizational Documents; 
 (d)    Enter into any bankruptcy, liquidation,
dissolution or winding-up of the Company (other than in connection with a sale transaction that is structured as a sale of all or substantially all of the assets of the Company); 

  
 5 

 (e)    Amend or modify the Organizational Documents in a
manner that adversely affects the Blackstone Holders’ or Founder Groups’ rights disproportionately as compared to other holders of Common Stock (taking into account and considering the rights of the Blackstone Holders or Founder Groups
prior to such amendment or modification); and 
 (f)    Make any agreement or arrangement to carry out
any of the matters referenced above under this Section 2.2. 
 2.3    Trust
Arrangements. At all times that a trust is a Stockholder of any Non-Blackstone Securities, there shall be a Company Trustee of such trust who shall either be (i) one of the Founders, (ii) the
director designated by the Founder Groups pursuant to Section 2.1(b)(i)(A) of this Agreement, (iii) an individual or corporate trustee with relevant industry experience chosen by one or both of the Founders in
consultation with the Sponsor, or (iv) in the event both Founders are deceased or incapacitated, a member of the Immediate Family of the Founder who is the settlor of the trust for such period until an individual or corporate trustee with
relevant industry experience is identified and appointed as trustee pursuant to the terms of the trust; provided that such time period shall not exceed 15 days following the first date on which both Founders are deceased or incapacitated.

 2.4    Founder Group Actions(a) . Any action taken by a Founder on behalf of his associated Founder Group
shall be deemed taken by such Founder Group; provided that, in the event a Founder cannot take such action due to death or disability, such actions that may be taken by a Founder Group shall be deemed taken by such Founder Group if the
holders of a majority of Securities held by such Founder Group consent to such action. 
 ARTICLE III 

TRANSFERS OF SECURITIES 

3.1    Restrictions on Transfer of Non-Blackstone Securities. Prior
to the third anniversary of the initial Public Offering, (the “Lapse Date”), no holder of Non-Blackstone Securities may Transfer any Non-Blackstone
Securities without the prior written consent of the Sponsor except in an Exempt Non-Blackstone Transfer; provided that the transfer restrictions in this Section 3.1 shall not
apply to (i) the Non-Blackstone Securities sold in the initial Public Offering and (ii) the percentage of Non-Blackstone Securities of each holder equal to the
percentage of Blackstone Securities sold by the Blackstone Holders in the initial Public Offering and in subsequent Public Offerings relative to the total number of Blackstone Securities held by the Blackstone Holders immediately prior to the
initial Public Offering. For the avoidance of doubt, following the Lapse Date, the transfer restrictions in this Section 3.1 shall not apply. 

3.2    Securities Act Compliance. No Securities may be transferred by a holder of
Non-Blackstone Securities (other than pursuant to an effective registration statement under the Securities Act) unless, if requested by the Company, such Stockholder first delivers to the Company an opinion of
counsel, which opinion of counsel shall be reasonably satisfactory to the Company, to the effect that such Transfer is not required to be registered under the Securities Act. 

  
 6 

 3.3    Certain Transferees Bound by Agreement. Subject to
compliance with the other provisions of this Article III, any Stockholder may Transfer any Securities held by such Stockholder in accordance with applicable law; provided, however, that if the Transfer is not made pursuant to a
Public Sale or a transaction the consummation of which will cause the termination of this Agreement pursuant to Article VI, then the transferor of such Security shall first deliver to the Company a written agreement of the proposed transferee
to become a Stockholder and to be bound by the terms of this Agreement (unless such proposed transferee is already a Stockholder). All Non-Blackstone Securities will continue to be Non-Blackstone Securities in the hands of any transferee (other than the Company, any Blackstone Holder or any transferee in a Public Sale). All Blackstone Securities will continue to be Blackstone Securities in the
hands of any transferee, except if the transferee is (i) the Company or any of its Subsidiaries, (ii) the Non-Blackstone Holders, (iii) a transferee in a transaction that constitutes a Change of
Control, or (iv) a transferee in a Public Sale. 
 3.4    Transfers in Violation of Agreement. Any Transfer
or attempted Transfer of any Securities in violation of any provision of this Agreement shall be void, and the Company shall not record such Transfer on its books or treat any purported transferee of such Securities as the owner of such Securities
for any purpose. 
 ARTICLE IV 

ADDITIONAL COVENANTS 

4.1    Pledges or Transfers. Upon the request of any Blackstone Holder that wishes to (x) pledge,
hypothecate or grant security interests in any or all of the shares of Common Stock held by it including to banks or financial institutions as collateral or security for loans, advances or extensions of credit or (y) transfer any or all of the
shares of Common Stock held by it, including to third party investors, the Company agrees to cooperate with such Blackstone Holder in taking any action reasonably necessary to consummate any such pledge, hypothecation, grant or transfer, including
without limitation, delivery of letter agreements to lenders in form and substance reasonably satisfactory to such lenders (which may include agreements by the Company in respect of the exercise of remedies by such lenders), instructing the transfer
agent to transfer any such shares of Common Stock subject to the pledge, hypothecation or grant into the facilities of The Depository Trust Company without restricted legends and cooperating in diligence or other matters as may reasonably be
requested by any Blackstone Holder in connection with a proposed transfer. 
 4.2    Spin-Offs or Split-Offs. In
the event that the Company effects the separation of any portion of its business into one or more entities (each, a “NewCo”), whether existing or newly formed, including without limitation by way of
spin-off, split-off, carve-out, demerger, recapitalization, reorganization or similar transaction, and any Stockholder will
receive equity interests in any such NewCo as part of such separation, the Company shall cause any such NewCo to enter into a Stockholders agreement with the Stockholders that provides the Stockholder Entities with rights vis-á-vis such NewCo that are substantially identical to those set forth in this Agreement. 

  
 7 

 ARTICLE V 

INFORMATION; VCOC 

5.1    Books and Records; Access. The Company shall, and shall cause its Subsidiaries to, keep proper books,
records and accounts, in which full and correct entries shall be made of all financial transactions and the assets and business of the Company and each of its Subsidiaries in accordance with generally accepted accounting principles. The Company
shall, and shall cause its Subsidiaries to, (a) permit the Stockholder Entities and their respective designated representatives (or other designees), at reasonable times and upon reasonable prior notice to the Company, to review the books and
records of the Company or any of such Subsidiaries and to discuss the affairs, finances and condition of the Company or any of such Subsidiaries with the officers of the Company or any such Subsidiary and (b) provide the Stockholder Entities
all information of a type, at such times and in such manner as is consistent with the Company’s past practice or that is otherwise reasonably requested by such Stockholder Entities from time to time (all such information so furnished pursuant
to this Section 5.1, the “Information”). Subject to Section 5.5, any Stockholder Entity (and any party receiving Information from a Stockholder Entity) who shall receive
Information shall maintain the confidentiality of such Information. Notwithstanding the foregoing, that the Company shall not be required to disclose any privileged Information of the Company so long as the Company has used commercially reasonable
efforts to enter into an arrangement pursuant to which it may provide such information to the Stockholder Entities without the loss of any such privilege. 

5.2    Tax Related Information. The Company shall promptly make available to the Stockholder Entities all
books, records and files of the Company and its Subsidiaries with respect to tax matters as may be reasonably requested by the Stockholder Entities and shall use reasonable efforts to comply with any requests by the Stockholder Entities for any tax-related information (including any applicable state withholdings) of any entity (i) which owns, directly or indirectly, all or a portion of the equity of the Company and (ii) in which any of the
Stockholder Entities and the Company’s management own, directly or indirectly, all or a portion of the equity. 

5.3    Certain Reports. The Company shall deliver or cause to be delivered to the Stockholder Entities, at
their request: 
 (a)    to the extent otherwise prepared by the Company, operating and capital
expenditure budgets and periodic information packages relating to the operations and cash flows of the Company and its Subsidiaries; and 

(b)    to the extent otherwise prepared by the Company, such other reports and information as may be
reasonably requested by the Stockholder Entities; provided, however, that the Company shall not be required to disclose any privileged information of the Company so long as the Company has used commercially reasonable efforts to enter into an
arrangement pursuant to which it may provide such information to the Stockholder Entities without the loss of any such privilege. 

  
 8 

 5.4    VCOC.

(a)    With respect to each Stockholder Entity that is intended to qualify its direct or indirect investment in the Company
as a “venture capital investment” as defined in the Department of Labor regulations codified at 29 CFR Section 2510.3-101 (the “Plan Asset Regulation”) (each, a “VCOC
Investor”), for so long as the VCOC Investor, directly or through one or more subsidiaries, continues to hold any Common Stock (or other securities of the Company into which such Common Stock may be converted or for which such Common Stock
may be exchanged), without limitation or prejudice of any of the rights provided to the Stockholder Entities hereunder, the Company shall, with respect to each such VCOC Investor: 

(i)    provide each VCOC Investor or its designated representative with: 

(A)    upon reasonable notice and at mutually convenient times, the right to visit and inspect any of the
offices and properties of the Company and its Subsidiaries and inspect and copy the books and records of the Company and its Subsidiaries; 

(B)    as soon as available and in any event within 45 days after the end of each of the first three
quarters of each fiscal year of the Company, consolidated balance sheets of the Company and its Subsidiaries as of the end of such period, and consolidated statements of income and cash flows of the Company and its Subsidiaries for the period then
ended prepared in conformity with generally accepted accounting principles in the United States applied on a consistent basis, except as otherwise noted therein, and subject to the absence of footnotes and to
year-end adjustments; 
 (C)    as soon as available and in any
event within 120 days after the end of each fiscal year of the Company, a consolidated balance sheet of the Company and its Subsidiaries as of the end of such year, and consolidated statements of income and cash flows of the Company and its
Subsidiaries for the year then ended prepared in conformity with generally accepted accounting principles in the United States applied on a consistent basis, except as otherwise noted therein, together with an auditor’s report thereon of a firm
of established national reputation; 
 (D)    to the extent the Company is required by law or pursuant to
the terms of any outstanding indebtedness of the Company to prepare such reports, any annual reports, quarterly reports and other periodic reports pursuant to Section 13 or 15(d) of the Exchange Act, actually prepared by the Company as soon as
available; and 
 (E)    upon written request by the VCOC Investor, copies of all materials provided to
the Board, subject to appropriate protections with respect to confidentiality and preservation of attorney-client privilege; provided, that, in each case, if the Company makes the information described in clauses (B), (C) and (D) of this
Section 5.4(a)(i) available through public filings on the EDGAR System or any successor or replacement system of the U.S. Securities and Exchange Commission, the requirement to deliver such information shall be deemed
satisfied; 

  
 9 

 (ii)    make appropriate officers and/or directors of
the Company available, and cause the officers and directors of its Subsidiaries to be made available, periodically and at such times as reasonably requested by each VCOC Investor, upon reasonable notice and at mutually convenient times, for
consultation with such VCOC Investor or its designated representative with respect to matters relating to the business and affairs of the Company and its Subsidiaries; 

(iii)    to the extent that the VCOC Investor requests to receive such information and rights, and to the
extent consistent with applicable Law or listing standards (and with respect to events which require public disclosure, only following the Company’s public disclosure thereof through applicable securities law filings or otherwise), inform each
VCOC Investor or its designated representative in advance with respect to any significant corporate actions, and to provide (or cause to be provided) each VCOC Investor or its designated representative with the right to consult with the Company and
its Subsidiaries with respect to such actions should the VCOC Investor elect to do so; provided, however, that this right to consult must be exercised within five days after the Company informs the VCOC Investor of the proposed corporate
action; provided, further, that the Company shall be under no obligation to provide the VCOC Investor with any material non-public information with respect to such corporate action; and 

(iv)    provide each VCOC Investor or its designated representative with such other rights of consultation
which the VCOC Investor’s counsel may determine in writing to be reasonably necessary under applicable legal authorities promulgated after the date hereof to qualify its investment in the Company as a “venture capital investment” for
purposes of the Plan Asset Regulation; provided that the parties agree that any such rights of consultation shall be of a nature consistent with those granted above and nothing in this Agreement shall be deemed to require the Company to grant
to the VCOC Investor any additional rights with respect to the governance or management of the Company. 
 (b)    The
Company agrees to consider, in good faith, the recommendations of each VCOC Investor or its designated representative in connection with the matters on which it is consulted as described above in this Section 5.4,
recognizing that the ultimate discretion with respect to all such matters shall be retained by the Company. 
 (c)    In
the event a VCOC Investor or any of its Affiliates Transfers all or any portion of their investment in the Company to an Affiliated entity that is intended to qualify its investment in the Company as a “venture capital investment” (as
defined in the Plan Asset Regulation), such Transferee shall be afforded the same rights with respect to the Company afforded to the VCOC Investor hereunder and shall be treated, for such purposes, as a third party beneficiary hereunder. 

(d)    In the event that the Company ceases to qualify as an “operating company” (as defined in the first
sentence of 2510.3-101(c)(1) of the Plan Asset Regulation), or the investment in the Company by a VCOC Investor does not qualify as a “venture capital investment” as

  
 10 

 
defined in the Plan Asset Regulation, then the Company and each Stockholder Entity will cooperate in good faith and take all reasonable actions necessary, subject to applicable Law, to preserve
the VCOC status of each VCOC Investor or the qualification of the investment as a “venture capital investment,” it being understood that such reasonable actions shall not require a VCOC Investor to purchase or sell any investments. 

(e)    For so long as the VCOC Investor, directly or through one or more subsidiaries, continues to hold any Common Stock
(or other securities of the Company into which such Common Stock may be converted or for which such Common Stock may be exchanged) and upon the written request of such VCOC Investor, without limitation or prejudice of any of the rights provided to
the Stockholder Entities hereunder, the Company shall, with respect to each such VCOC Investor, furnish and deliver a letter covering the matters set forth in Sections 5.4(a), 5.4(b), 5.4(c) and 5.4(d) hereof in a form
and substance satisfactory to such VCOC Investor. 
 (f)    In the event a VCOC Investor is an Affiliate of a
Stockholder Entity, as described in Section 5.4(a) above, such affiliated entity shall be afforded the same rights with respect to the Company and afforded to the Stockholder Entity under this
Section 5.4 and shall be treated, for such purposes, as a third party beneficiary hereunder. 

5.5    Information Sharing. Each party hereto acknowledges and agrees that Designees may share any information
concerning the Company and its Subsidiaries received by them from or on behalf of the Company or its designated representatives with each Stockholder and its designated representatives (subject to such Stockholder’s obligation to maintain the
confidentiality of Confidential Information in accordance with Section 7.4). 
 ARTICLE VI 

AMENDMENT AND TERMINATION 

6.1    Amendment and Waiver. Except as otherwise provided herein, no modification, amendment or waiver of any
provision of this Agreement shall be effective against the Company, the Founders or the Stockholders unless such modification, amendment or waiver is approved in writing by the Company (upon approval by the Board); provided that no such
modification, amendment or waiver may adversely affect the rights or obligations hereunder of the Founders or the Founder Groups unless approved in writing by each Founder (or such Founder’s Founder Group if such Founder is unable to provide
approval due to death, illness or incapacity) adversely affected by such amendment, modification or waiver; provided, further, that no such modification, amendment or waiver may adversely affect the rights or obligations hereunder of
the Blackstone Holders unless approved in writing by the Sponsor. The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party
thereafter to enforce each and every provision of this Agreement in accordance with its terms. 
 6.2    Termination
of Agreement. This Agreement (other than Section 2.1(h)) will terminate in respect of the Founders, the Company and all Stockholders (a) upon the dissolution, liquidation or
winding-up of the Company or (b) upon the consummation of a Change of Control. 

  
 11 

 6.3    Termination as to a Party. Any Person who ceases to hold
any Securities shall cease to be a Stockholder and shall have no further rights or obligations under this Agreement. 
 ARTICLE VII 

MISCELLANEOUS 

7.1    Certain Defined Terms. As used in this Agreement, the following terms shall have the meanings set forth or
as referenced below: 
 “Affiliate” of any particular Person means any other Person Controlling, Controlled by or under
common Control with such particular Person or, in the case of a natural Person, any member of such Person’s Immediate Family. 

“Agreement” has the meaning set forth in the preface. 

“Blackstone Designee” has the meaning set forth in Section 2.1(b). 

“Blackstone Holders” has the meaning set forth in the preface. 

“Blackstone Securities” means (a) Common Stock or Common Stock Equivalents held by any Blackstone Holder and
(b) any securities of the Company issued with respect to the securities referred to in clause (a) above by way of a payment-in-kind, stock dividend, or stock
split or in connection with a combination of shares, exchange, conversion, recapitalization, merger, consolidation or other reorganization, or otherwise. 

“Beneficially Own” has the meaning set forth in Rule 13d-3 promulgated under the
Exchange Act. 
 “Board” means the board of directors of the Company. 

“Business Day” means any day on which commercial banks are open for business in New York, New York. 

“Change of Control” means (i) the sale or disposition, in one or a series of related transactions, of all or
substantially all of the assets of the Company and its Subsidiaries, as a whole, to any “person” or “group” (as such terms are defined in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) other than Sponsor or its affiliates
(as defined in Rule 501(b) of the Securities Act) or (ii) any person or group, other than Sponsor or its Affiliates, is or becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the total voting power of the voting stock of the Company, including by way of merger, consolidation or otherwise and Sponsor ceases to
control the Board. 
 “Common Stock” means, collectively, the Class A common stock of the Company, par value $0.01 per
share, and the Class B common stock of the Company, par value $0.01 per share. 
 “Common Stock Equivalents” means
(without duplication with any Common Stock or other Common Stock Equivalents) rights, warrants, options, convertible securities, or exchangeable securities or indebtedness, or other rights, exercisable for or convertible or

  
 12 

 
exchangeable into, directly or indirectly, Common Stock or securities exercisable for or convertible or exchangeable into Common Stock, whether at the time of issuance or upon the passage of time
or the occurrence of some future event. 
 “Company” has the meaning set forth in the preface. 

“Company Trustee” shall mean any trustee or other trust fiduciary with power to act unilaterally with respect to any Non-Blackstone Securities held in a trust that is a Stockholder. 
 “Competing Business”
has the meaning set forth in Section 7.3. 
 “Competitor” means any Person that is reasonably
determined by the Board to be a competitor of the Company or any of its Subsidiaries in any material respect. For purposes hereof, without limiting the foregoing, any Person with substantial operations in the business of business process
outsourcing, including the provision of outsourced customer service and content management, shall be presumed to be a Competitor unless the Board otherwise determines; provided, however, that for purposes of this Agreement, Sponsor and
its Affiliates shall not be deemed a Competitor solely due to its direct or indirect investment (through a portfolio company or otherwise) in a Person where such Person would be deemed a Competitor. 

“Confidential Information” has the meaning set forth in Section 7.4(a). 

“Confidentiality Affiliates” has the meaning set forth in Section 7.4(a). 

“control” (including the terms “controlled by” and “under common control with”) means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as trustee or executor, by contract or otherwise, including the ownership, directly
or indirectly, of securities having the power to elect a majority of the board of directors or similar body governing the affairs of such Person. 

“Designee” has the meaning set forth in Section 2.1(b). 

“Distribution” means each dividend or distribution made by the Company or any of its Subsidiaries to its or their
shareholders, whether in cash, property, or securities of the Company and whether by dividend, liquidating distributions, repurchase, redemption or other acquisition for value of any Security. 

“Excepted Issuances” means the issuance, granting or sale of any Securities or other securities convertible into or
exchangeable for any such Securities, (i) in connection with any Public Offering, any conversion for an initial Public Offering or any initial Public Offering of a Subsidiary of the Company, (ii) pursuant to any present or future employee,
officer or director benefit plan or program of or assumed by the Company or any of its Subsidiaries in an amount not greater than 15% of the outstanding Securities on a fully diluted basis, (iii) as consideration in any merger, consolidation,
acquisition for stock, business combination or any similar extraordinary transaction, (iv) the issuance of Securities or other equity securities of the Company as a dividend or distribution to all holders of Securities, or (v) a
reclassification of (or similar action with respect to) all Securities into a greater or lesser number of Securities. 

  
 13 

 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and
the rules and regulations of the SEC promulgated thereunder. 
 “Exempt Non-Blackstone
Transfer” means a Transfer of Non-Blackstone Securities (a) upon the death of the holder pursuant to the applicable laws of descent and distribution, (b) solely to or among such transferor
Founder’s Permitted Group, (c) to Sponsor or any of its Affiliates or (f) upon the death of a Founder, from one member of a deceased Founder’s Founder Group to or among the other Founder and the Permitted Group of the other
Founder. 
 “Founder” or “Founders” has the meaning set forth in the preface. 

“Founder Designee” has the meaning set forth in Section 2.1(b). 

“Founder Group” means the Maddock Group or the Weir Group. For purposes of this Agreement, (a) with respect to Bryce
Maddock, the Maddock Group and (b) with respect to Jaspar Weir, the Weir Group. 
 “Founder Group Designee” means a
Designee appointed by a Founder Group. 
 “Founder Group Minimum Ownership Condition” means that a Founder Group
Beneficially Owns, in the aggregate, a number of Securities representing an Ownership Percentage of at least 5%. 
 “Immediate
Family” means an individual’s parents, spouse, child (natural or adopted), or any other direct lineal descendant of a parent of such individual (or his or her spouse). 

“Information” has the meaning set forth in Section 5.1. 

“Joint Founder Designee” has the meaning set forth in Section 2.1(b). 

“Lapse Date” has the meaning set forth in Section 3.1. 

“Law” means any statute, law, regulation, ordinance, rule, injunction, order, decree, governmental approval, directive,
requirement, or other governmental restriction or any similar form of decision of, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental Authority. 

“Maddock Group” means (i) the Stockholders listed on Schedule B attached hereto; and (ii) any transferee of
any Securities held by the Stockholders in clause (i) of this definition who is in the Permitted Group of Bryce Maddock. 

“NewCo” has the meaning set forth in Section 4.2. 

“New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

  
 14 

 “Non-Blackstone Holders” has the
meaning set forth in the preface. 
 “Non-Blackstone Securities” means Common Stock
or Common Stock Equivalents held by any Non-Blackstone Holder and any such securities of the Company issued by way of a
payment-in-kind, stock dividend, or stock split or in connection with a combination of shares, exchange, conversion, recapitalization, merger, consolidation or other
reorganization, or otherwise. 
 “Organizational Documents” means the Certification of Incorporation and Bylaws of the
Company. 
 “Ownership Percentage” means, for each Stockholder, the percentage obtained by dividing the number of
Securities held by such Stockholder by the total number of outstanding Securities of the Company on a fully diluted basis. 

“Permitted Group” means, with respect to any Founder, (i) any transferee of Securities held by a member of such
Founder’s Founder Group made for bona fide estate planning purposes, either during lifetime or on death by testamentary instrument or intestacy; provided that such transferee is the parent or spouse , or with the written consent of the
Sponsor, other close family members, (ii) any trust of which such Founder is a settlor and any beneficiary of such trust; provided that such beneficiary is limited to a member of such Founder’s Immediate Family, or with the written
consent of the Sponsor, other close family member of such Founder, (iii) any partnership, limited liability company or similar vehicle that is a wholly owned and controlled Affiliate of any of the foregoing; provided that no
“benefit plan investor” within the meaning of Section 3(42) of the Employee Retirement Income Security Act of 1974, as amended, may be a member of the Permitted Group and (iv) upon the death of a Founder, the other Founder Group
solely to the extent necessary to satisfy the obligations under that certain Conditional Stock Transfer Agreement by and among the Founders, the members of the Founder Groups and the Company dated on or about the date hereof. 

“Person” means an individual, a partnership, a joint venture, a corporation, an association, a joint stock company, a limited
liability company, a trust, an unincorporated organization or a government or any department or agency or political subdivision thereof. 

“Plan Asset Regulation” has the meaning set forth in Section 5.4(a). 

“Public Offering” means a sale of Common Stock to the public in an offering pursuant to an effective registration statement
filed with the SEC pursuant to the Securities Act, as then in effect, provided that a Public Offering shall not include an offering made in connection with a business acquisition or combination or an employee benefit plan. 

“Public Sale” means a sale of Securities pursuant to a Public Offering or a Rule 144 Sale. 

“Replacement Nominee” has the meaning set forth in Section 2.1(b)(iii). 

“Representatives” means, with respect to any Person, any director, officer, employee, principal, partner, manager, member,
financial advisor, attorney, accountant, consultant, agent, advisor or other authorized representative of such Person. 

  
 15 

 “Rescue Financing” means financing provided to the Company or any of its
Subsidiaries, which financing is reasonably required to (i) remedy a breach or default (or potential breach or default) by the Company or any of its Subsidiaries under any debt financing agreements to which the Company or any of its
Subsidiaries are party, (ii) provide liquidity to the Company or any of its Subsidiaries to the extent necessary to fund their then-current operations, under circumstances where the failure to provide such liquidity would reasonably be expected
to be materially adverse to the Company, or (iii) comply with applicable capital requirements laws, rules or regulations. 

“Rule 144 Sale” means a sale of Securities to the public through a broker, dealer or market-maker pursuant to
the provisions of Rule 144 adopted under the Securities Act (or any successor rule or regulation). 
 “SEC” means the
Securities and Exchange Commission. 
 “Securities” means, collectively, the Blackstone Securities and the Non-Blackstone Securities. 
 “Securities Act” means the Securities Act of 1933, as
amended from time to time. 
 “Sponsor” has the meaning set forth in the preface. 

“Subsidiary” means any corporation, limited liability company, partnership or other entity with respect to which another
specified entity has the power to vote or direct the voting of sufficient securities to elect directors (or comparable authorized persons of such entity) having a majority of the voting power of the board of directors (or comparable governing body)
of such entity. 
 “Stockholder” has the meaning set forth in the preface. 

“Stockholder Entity” means any Stockholder and each of its Affiliates and their respective successors. 

“Total Number of Directors” means the total number of directors comprising the Board from time to time. 

“Transfer” means (in either the noun or the verb form, including with respect to the verb form, all conjugations thereof
within their correlative meanings) with respect to any security, the gift, sale, assignment, transfer, pledge, hypothecation or other disposition (whether for or without consideration, whether directly or indirectly, and whether voluntary,
involuntary or by operation of law) of such Security or any interest therein. 
 “VCOC Investor” has the meaning set forth
in Section 5.4(a). 
 “Weir Group” means (i) the Stockholders listed on Schedule C
attached hereto; and (ii) any transferee of any Securities held by the Stockholders in clause (i) of this definition who is in the Permitted Group of Jaspar Weir. 

  
 16 

 7.2    Legends. 

(a)    Stockholders Agreement. The Securities and each instrument, certificate or book-entry, if any, issued in
exchange for or upon the Transfer of any such Securities (if such securities remain subject to this Agreement after such Transfer) shall bear a legend (as appropriately completed under the circumstances) in substantially the following form (and a
stop-transfer order may be placed against transfer of such Securities): 
 “THE SECURITIES REPRESENTED BY THIS [CERTIFICATE][BOOK-ENTRY]
CONSTITUTE “NON-BLACKSTONE SECURITIES” UNDER A CERTAIN AMENDED AND RESTATED STOCKHOLDERS AGREEMENT DATED AS OF
[                ], 2021 AMONG THE ISSUER OF SUCH SECURITIES (THE “COMPANY”) AND CERTAIN OF THE COMPANY’S STOCKHOLDERS AND, AS SUCH, ARE SUBJECT TO
CERTAIN VOTING PROVISIONS, PURCHASE RIGHTS AND RESTRICTIONS ON TRANSFER SET FORTH IN THE STOCKHOLDERS AGREEMENT. A COPY OF SUCH STOCKHOLDERS AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE COMPANY TO THE HOLDER HEREOF UPON WRITTEN REQUEST.”

 (b)    Restricted Securities. The Securities and each instrument, certificate or book-entry, if any, issued in
exchange or upon the Transfer of any Securities shall bear a legend substantially in the following form (and a stop-transfer order may be placed against transfer of such Securities): 

“THE SECURITY REPRESENTED BY THIS [CERTIFICATE][BOOK-ENTRY] HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND MAY NOT BE OFFERED OR SOLD UNLESS IT HAS BEEN REGISTERED UNDER THE SECURITIES ACT OR UNLESS AN EXEMPTION FROM REGISTRATION IS AVAILABLE (AND, IN SUCH CASE, AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
SHALL HAVE BEEN DELIVERED TO THE COMPANY TO THE EFFECT THAT SUCH OFFER OR SALE IS NOT REQUIRED TO BE REGISTERED UNDER THE SECURITIES ACT).” 

(c)    Removal of Legends. Whenever in the opinion of the Company and counsel reasonably satisfactory to the
Company (which opinion shall be delivered to the Company in writing) the restrictions described in any legend set forth above cease to be applicable to any Securities, the holder thereof shall be entitled to receive from the Company, without expense
to the holder, a new instrument, certificate or book-entry not bearing a legend stating such restriction. 
 7.3    Non-Compete(a) . At all times during which either Founder is on the Board or has a right to be a designee director and for a period of two years thereafter, except on behalf of the Company or except with the
written consent of the Company, each Founder shall not, directly or indirectly, render services to, own, manage, operate, control, invest or acquire an interest in, whether as a proprietor, partner, stockholder, member, director, officer, manager,
employee, consultant, joint venturer, debt or equity investor, lessor agent or other representative, any Person that is known by such Founder to engage in the line of business (and any lines of business the Company has active plans to engage) of the
Company and its Subsidiaries (which, if neither 

  
 17 

 
Founder is on the Board and neither Founder has a right to be a designee director at the time, shall be limited to the lines of business of the Company as of the date that such Founder is no
longer on the Board) in each case anywhere in the world (collectively, the “Competing Business”) (including directly or indirectly as a division or group of a larger organization) or otherwise engage in or conduct (whether as an
owner, operator, employee, officer, director, consultant, advisor, partner, representative or otherwise) a Competing Business; provided that the ownership of less than 5% of the outstanding stock of any class of any corporation (other than
any direct competitor of the Company in the business process outsourcing services space) shall not be deemed to be engaging in a Competing Business solely by reason of such ownership and provided, further, that this Section shall not preclude a
Founder from rendering advice not for compensation to a Competing Business on a casual or occasional basis. Notwithstanding anything herein to the contrary, the Company hereby consents to each Founder’s (a) ownership of less than
[    ]% of the outstanding stock of any class of equity in the companies listed on Schedule A; and (b) role as board member or advisor to the following companies:
[                ]. For purposes of this Section 7.3, the capital stock of a corporation owned by Founder shall not include the capital stock
of a corporation owned of record by a mutual fund or similar investment vehicle, provided that Founder does not exercise a controlling interest or exercise control over investment decisions of such mutual fund or investment vehicle. 

7.4    Confidentiality. 

(a)    Each Non-Blackstone Holder agrees that it shall (and shall cause its
Affiliates and its and their Representatives) (collectively, other than Affiliates that are Competitors, the “Confidentiality Affiliates”) (i) hold confidential and not disclose (other than by a Stockholder to its Confidentiality
Affiliates having a reasonable need to know in connection with the permitted purposes hereunder or in such Stockholder’s capacity as an employee of the Company or any of its Subsidiaries), without the prior approval of the Board, all
confidential or proprietary written, recorded or oral information or data (including research, developmental, engineering, manufacturing, technical, marketing, sales, financial, operating, performance, cost, business and process information or data,
know-how and computer programming and other software techniques) provided or developed by the Company and any of its Subsidiaries, another Stockholder or its Confidentiality Affiliates in connection herewith
or with the business of the Company and its Subsidiaries, whether such confidentiality or proprietary status is indicated orally or in writing or in a context in which any of the Company and any of its Subsidiaries or the disclosing Stockholder or
any of their Confidentiality Affiliates reasonably communicated, or the receiving Stockholder or its Confidentiality Affiliates should reasonably have understood, that the information should be treated as confidential, whether or not the specific
words “confidential” or “proprietary” are used (“Confidential Information”) and (ii) use such Confidential Information only for the purposes of performing its obligations hereunder, performing activities in
its capacity as an employee of the Company or any of its Subsidiaries and carrying on the business of the Company and monitoring its investment in the Company; provided, however, that Stockholders may disclose any such Confidential
Information in connection with a Transfer of Securities permitted under this Agreement, to prospective 

  
 18 

 
purchasers of Securities from a Stockholder, after such prospective purchaser has entered into a non-disclosure agreement reasonably acceptable to the
Company, as well as to such prospective purchaser’s legal counsel, auditors, agents and representatives. Notwithstanding the foregoing, Stockholders may disclose any such Confidential Information on a confidential basis to investors of a
Stockholder or its Confidentiality Affiliates, subject to such investors having agreed to maintain the confidentiality of any such Confidential Information; provided, however, that each Stockholder shall not (and shall cause its
Confidentiality Affiliates or investors of such Stockholder or its Confidentiality Affiliates not to) disclose any Confidential Information to any Person that is a Competitor of the Company. Each Stockholder agrees that it shall be responsible and
liable for any breach of this Section 7.4 by its Confidentiality Affiliates or investors of such Stockholder or its Confidentiality Affiliates (as if such Confidentiality Affiliates or investors were parties to and bound by
the provisions of this Section 7.4 by which such Stockholder is bound). 
 (b)    The
obligations contained in Section 7.4(a) shall not apply, or shall cease to apply, to Confidential Information if or when, and to the extent that, such Confidential Information (i) was, or becomes through no breach of
the receiving Stockholder’s or its Confidentiality Affiliates’ obligations hereunder, known to the public, (ii) becomes known to the receiving Stockholder or its Confidentiality Affiliates from other sources under circumstances not
involving any breach of any confidentiality obligation between such source and the disclosing Stockholder’s or discloser’s Confidentiality Affiliates or a third party, (iii) is independently developed by the receiving Stockholder or
its Confidentiality Affiliates, or (iv) is required to be disclosed by law, governmental regulation or applicable legal process; provided that to the extent permitted by law, such Stockholder shall notify the Company promptly of such
request or requirement so that the Company may seek an appropriate protective order or other appropriate relief; provided, further, that in the absence of a protective order or other appropriate relief, the Stockholder shall use
commercially reasonable efforts to obtain an order or other assurance that confidential treatment will be accorded to such portion of the information required to be disclosed as the Company shall designate. 

7.5    Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provision or any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. 

7.6    Entire Agreement. This Agreement and the other documents and agreements referred to herein or entered into
concurrently herewith embody the entire agreement and understanding of the parties hereto in respect of the subject matter contained herein; provided that such other agreements and documents shall not be deemed to be a part of, a modification of or
an amendment to this Agreement. There are no restrictions, promises, representations, warranties, covenants or undertakings, other than those expressly set forth or referred to herein. This Agreement supersedes all prior agreements and
understandings between the parties with respect to such subject matter, including that certain Shareholder Agreement, dated as of October 1, 2018, among the Company, the Sponsor, the Non-Blackstone
Holders party thereto and the Founders, which agreement is amended and restated by this Agreement. This Agreement is not intended to, and does not, confer upon any Person other than the parties hereto any rights or remedies. 

  
 19 

 7.7    Successors and Assigns. Except as otherwise provided
herein, this Agreement shall bind and inure to the benefit of and be enforceable by the Company and its successors and assigns and the Stockholders and any subsequent holders of Securities and the respective successors and assigns of each of them,
so long as they hold Securities. Other than in a Change of Control or a Public Sale, any subsequent holders of Securities or New Securities shall become a party to this Agreement by executing and delivering a counterpart signature page to this
Agreement. No action or consent by the Stockholders shall be required for such joinder to this Agreement by such subsequent holder of Securities or New Securities, so long as such holder of Securities or New Securities has agreed in writing to be
bound by all of the obligations applicable to such holder of Securities or New Securities hereunder. 

7.8    Counterparts. This Agreement may be executed in separate counterparts each of which shall be an original and
all of which taken together shall constitute one and the same agreement. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Agreement or any document to
be signed in connection with this Agreement shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed
signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means. 

7.9    Remedies. The Company, the Founders and the Stockholders shall be entitled to enforce their rights under
this Agreement specifically, to recover damages by reason of any breach of any provision of this Agreement (including costs of enforcement) and to exercise all other rights existing in their favor. The parties hereto agree and acknowledge that money
damages may not be an adequate remedy for any breach of the provisions of this Agreement and that the Company or any Stockholder may in its or his sole discretion apply to any court of law or equity of competent jurisdiction for specific performance
or injunctive relief (without posting a bond or other security) in order to enforce or prevent any violation of the provisions of this Agreement. 

7.10    Notices. Any notice, designation, request, request for consent or consent provided for in this Agreement
shall be in writing and shall be either personally delivered, or mailed first class mail (postage prepaid) or sent by reputable overnight courier service (charges prepaid) to the Company at the address set forth below and to any other recipient at
the address indicated on the Company’s records, or at such address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. Notices will be deemed to have been given hereunder
if (i) delivered personally, when delivered at the address specified in this Section 7.10, (ii) sent by facsimile or electronic mail, when such facsimile is transmitted to the facsimile number specified in this
Section 7.10 or on the first business day after when such electronic mail is sent to the e-mail address specified in this Section 7.10, or (iii) sent by
reputable overnight courier service, one day after deposit with such service. 

  
 20 

 If to the Company: 

TaskUs, Inc. 
 1650 Independence
Drive, Suite 100 
 New Braunfels, Texas 78132 

Attention:    Jeffrey Chugg, Vice President, Legal 

Email:         jeffrey.chugg@taskus.com 

If to a Stockholder, to the address across such Stockholder’s name and set forth on Exhibit A. 

If to a Founder or a Founder Group, solely with respect to such Founder or Founder Group: 

Bryce Maddock 

Attention:    Bryce Maddock 

          605 S. 3rd Street 

          Austin, TX 78704 

Email:         Bryce Maddock@gmail.com 

Jaspar Weir 

Attention:    Jaspar Weir 

          311 Bowie Street 

          Unit 1303 

          Austin, TX 78703 

Email:         Jaspar@taskus.com 

A copy of each notice given to the Company shall be given to Sponsor (and no notice to the Company shall be effective until such copy is
delivered to Sponsor) at the following addresses: 
 BCP FC Aggregator LP 

c/o The Blackstone Group L.P. 

345 Park Avenue 
 New York, NY
10154 
 Attention:    Amit Dixit 

          Mukesh Mehta 

Facsimile:   (212) 583-5710 

Email:         Dixit@Blackstone.com 

          Mukesh.Mehta@Blackstone.com 

7.11    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State
of New York. 
 7.12    Descriptive Headings. The descriptive headings of this Agreement are inserted for
convenience only and do not constitute a part of this Agreement. 

  
 21 

 7.13    Grant of Consent. Any vote, consent or approval of,
or designation by, or other action of, the Founder Group or the Sponsor hereunder shall be effective if notice of such vote, consent, approval, designation or action is provided in accordance with Section 7.10 hereof by the
Founder Group or the Sponsor as of the latest date any such notice is so provided to the Company. 
 [SIGNATURE PAGES FOLLOW] 

  
 22 

 IN WITNESS WHEREOF, the parties hereto have executed this Stockholders Agreement on the day
and year first above written. 
  

			
	TASKUS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	BCP FC Aggregator LP
		
	By:	 	  

	Name:	 	
	Title:	 	

 IN WITNESS WHEREOF, the parties hereto have executed this Stockholders Agreement on the day
and year first above written. 
  

			
	NON-BLACKSTONE HOLDERS:
	
	BRYCE MADDOCK FAMILY TRUST
		
	By:	 	  

	Name:	 	Bryce Maddock
	Title:	 	Trustee
	
	THE MADDOCK 2015 IRREVOCABLE TRUST
		
	By:	 	  

	Name:	 	Bryce Maddock
	Title:	 	Trustee
	
	JASPAR WEIR FAMILY TRUST
		
	By:	 	  

	Name:	 	Jaspar Weir
	Title:	 	Trustee
	
	THE WEIR 2015 IRREVOCABLE TRUST
		
	By:	 	  

	Name:	 	Jaspar Weir
	Title:	 	Trustee

 IN WITNESS WHEREOF, the parties hereto have executed this Stockholders Agreement on the day
and year first above written. 
  

	
	FOUNDERS:
	
	  

	Bryce Maddock
	
	  

	Jaspar Weir

 Schedule A 

 Schedule B 

Maddock Group 

1.    The Bryce Maddock Family Trust 

2.    The Maddock 2015 Irrevocable Trust 

 Schedule C 

Weir Group 

1.    Jaspar Weir Family Trust 

2.    The Weir 2015 Irrevocable Trust 

 Exhibit A 

Notice information of Stockholders 
  

			
	 Stockholders
	  	 Address

	 BCP FC Aggregator LP
	  	 BCP FC Aggregator LP

c/o The Blackstone Group L.P.

345 Park Avenue

New York, NY 10154

Attention:         Amit Dixit

                   
      Mukesh Mehta
 Facsimile:        (212) 583-5710
 Email:
             Dixit@Blackstone.com

                   
      Mukesh.Mehta@Blackstone.com

		
	 The Bryce Maddock Family Trust
	  	 Bryce Maddock

Attention:        Bryce Maddock

        605 S. 3rd
Street
         Austin, TX 78704

Email:             Bryce Maddock@gmail.com

		
	 The Maddock 2015 Irrevocable Trust
	  	 Bryce Maddock

Attention:        Bryce Maddock

        605 S. 3rd
Street
         Austin, TX 78704

Email: Bryce Maddock@gmail.com

		
	 Jaspar Weir Family Trust
	  	 Jaspar Weir

Attention:        Jaspar Weir

        311 Bowie Street

        Unit 1303

        Austin, TX 78703

Email:             Jaspar@taskus.com

		
	 The Weir 2015 Irrevocable Trust
	  	 Jaspar Weir

Attention:        Jaspar Weir

        311 Bowie Street

        Unit 1303

        Austin, TX 78703

Email:             Jaspar@taskus.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]